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Breast cancer is the leading cause of cancer-related death
in women worldwide. Expression of the WWOX tumor
suppressor is absent or reduced in a large proportion of
breast tumors suggesting that loss of WWOX may
contribute to breast tumorigenesis. Wwox-deﬁcient mice
die by 3–4 weeks of age precluding adult tumor analysis.
To evaluate the effect of WWOX-altered expression on
mammary tumor formation, theWwox-heterozygous allele
was back crossed onto the C3H mammary tumor-susceptible
genetic background (WwoxC3Hþ /) and incidence of
mammary tumor formation was evaluated. Although 50%
of the femaleWwoxC3Hþ / mice developed mammary carci-
nomas, only 7% ofWwoxC3Hþ /þ mice did. Intriguingly,
mammary tumors in WwoxC3Hþ / mice frequently lost
WWOX protein expression suggesting a genetic pre-
disposition toward mammary tumorigenesis. Immuno-
histochemical staining of hormone receptors revealed loss
of estrogen receptor-a (ER) and progesterone receptor in
the majority of these tumors. In vitro, depletion of WWOX
in MCF7 ER-positive cells led to reduced ER expression
and reduced sensitivity to tamoxifen and estrogen treatment
and was associated with enhanced survival and anchorage-
independent growth. Finally, cDNA array analyses of murine
normal mammary epithelial cells and mammary tumors
identiﬁed 163 signiﬁcantly downreguated and 129 upregu-
lated genes in the tumors. The majority of differentially
expressed genes were part of pathways involved in cellular
movement, cell-to-cell signaling and interaction, cellular
development, cellular growth and proliferation and cell death.
These changes in gene expression of mouse mammary
tumors in WwoxC3Hþ / mice resemble, at least in part,
human breast cancer development. Our ﬁndings demon-
strate the critical role that the WWOX tumor suppressor
gene has in preventing tumorigenesis in breast cancer.
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Introduction
Breast cancer is still one of the most common types
of tumors, affecting one woman out of eight, and is the
second leading cause of cancer death in women in the
USA (Jemal et al., 2010). The model of breast cancer
progression suggests that its development involves
deﬁned pathological and clinical stages, starting with
ductal hyperproliferation, with subsequent evolution
into in situ and invasive carcinomas, and ﬁnally into
metastatic disease (Polyak, 2007). Genome-wide micro-
array and copy number analyses revealed that breast
tumors exhibit a diverse pattern of genetic changes when
compared with normal mammary gland epithelial cells
(Perou et al., 2000). Although enormous advances have
been made in understanding breast cancer, the etiology
and molecular signaling pathways that contribute to
breast cancer formation remain largely elusive.
The WWOX gene encoding a protein with tumor
suppressor function, a WW domain-containing oxi-
doreductase (Del Mare et al., 2009), was originally
identiﬁed as a putative tumor suppressor in breast
cancer as it lies in a fragile genomic region (FRA16D)
that is frequently altered in pre-neoplastic and neoplas-
tic lesions (Bednarek et al., 2000; Ried et al., 2000).
Indeed, expression of WWOX is deregulated in two-
thirds of breast cancer cases (Guler et al., 2005; Nunez
et al., 2005). We and others have recently reported that
WWOX loss is a frequent event in breast cancers that
are negative for estrogen receptor (ER), progesterone
receptor (PR) and HER2 (triple negative (Sorlie et al.,
2001)) and that loss of WWOX expression is associ-
ated with nodal metastasis and unfavorable outcome
(Aqeilan et al., 2007a; Guler et al., 2009)). Loss of
heterozygosity and hypermethylation affecting WWOX
have been reported as main causes of WWOX
alterations in breast tumors (Bednarek et al., 2000;
Iliopoulos et al., 2007). Furthermore, ectopic expression
of WWOX in WWOX-negative breast cancer cells
suppresses tumorigenicity (Iliopoulos et al., 2007).
These ﬁndings suggest that alteration of WWOX
expression may have roles in the pathogenesis of breast
cancer.
Recently, we generated a mouse carrying a targeted
deletion of the Wwox gene (Aqeilan et al.,
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2007c). Spontaneous osteosarcomas were observed
in juvenile Wwox-null mice before their death,
whereas targeted loss of one allele increased the
incidence of spontaneous and chemically induced
lung and forestomach tumors (Aqeilan et al., 2007b, c;
Kurek et al., 2010) thus conﬁrming Wwox bona ﬁde
tumor suppressor function. At the biochemical level,
cumulative evidence suggests that WWOX has an
indispensable role in several signaling pathways (Salah
et al., 2010), however, the molecular mechanism of
WWOX tumor suppressor function remains largely
unknown.
In this study, we set out to determine whether targeted
ablation of Wwox in mice is associated with mammary
tumor formation. To this end, we partially trans-
ferred the Wwoxþ / allele into the C3H mammary
tumor-susceptible genetic background mice and moni-
tored mammary tumor development. We found that
Wwoxþ / mice are signiﬁcantly more prone to
spontaneous mammary tumor formation as compared
with wild-type (Wwoxþ /þ ) control littermates and
that these tumors closely resemble human breast
cancers. Our ﬁndings provide the ﬁrst in vivo evidence
that WWOX has critical roles in the pathogenesis of
breast cancer.
Results and discussion
Mammary tumor incidence in C3H-Wwox mice
We previously reported thatWwoxþ / mice on B6-129
mixed background develop higher incidence of lung
tumors as compared with Wwoxþ /þ mice (Aqeilan
et al., 2007c). We also noted that some of these mice
develop mammary tumors though with very low
penetrance (data not shown). These data prompted us
to examine the effect of WWOX altered expression on
mammary tumor formation using the C3H mammary
tumor-susceptible genetic background. The Wwox-
heterozygous allele was back crossed onto the C3H
background for three rounds (N3/F1; B87% purity)
and mammary tumor burden compared with wild-type
littermate animals was assessed. Monitoring of mice for
18-months revealed that WwoxC3Hþ / developed
mammary tumors earlier and at a higher frequency
than WwoxC3Hþ /þ mice did. In particular, 50% (9/18)
of WwoxC3Hþ / mice developed mammary tumors
compared with 7% (1/14) of WwoxC3Hþ /þ mice
(Table 1). The number of tumor-bearing animals among
WwoxC3Hþ / mice was 7-fold higher (P¼ 0.019) than
that of wild-type mice (Table 1). The incidence of tumors
per mouse inWwoxC3Hþ / mice was 11-fold higher than
Table 1 Characterization and incidence of mammary tumors in WwoxC3Hþ / and WwoxC3Hþ /þ mice
Mouse # Grade Histology WWOX ER PR CK14
M21 G-III IDC Neg Neg Neg Neg
M22 G-III IDC Neg Neg Neg Neg
M23 G-III IDC Red Neg Pos Neg
M24 G-III IDC with metaplastic SCC Neg Neg Neg Pos
M25 G-I/II IDC Red Pos n/a Neg
M26-T G-III IDC Red Neg Neg Pos
M26 T-2F G-III IDC, þDCIS Neg Neg Neg Pos
M26-T3 G-I DCIS with metaplastic SCC Pos Pos Pos Pos
M27-N Normal Pos Pos n/a Pos
M27-1 G-III IDC with metaplastic SCC Neg Neg Neg Pos
M27-T2 G-III IDC Neg Pos Pos Pos
M27-T4 G-II IDC Neg Neg Neg Pos
M27-T5 G-III IDC Neg Neg Neg Pos
M28-N Normal Pos Pos Pos Pos
M-29 G-III IDC Red n/a n/a Pos
M30N Normal, per-lobular inﬂammation Pos n/a n/a Pos
M31 N (WT) Normal Pos Pos Pos Pos
M35T G-III IDC, þDCIS Red n/a n/a Pos
M35 N Normal Pos Pos Pos Pos
HET WT P-value
Total no mice 18 14
Tumor incidence 9/18 (50%) 1/14 (7%) 0.019
Tumor/mouse 14/18 (78%) 1/14 (7%) o0.0001
Abbreviations: CK14, cytokeratine 14; DCIS, ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinomas; n/a, not available;
PR, progesterone receptor; SSC, squamous cell carcinoma; WT, wild type.
Three back-crosses of Wwox-heterozygous (Wwoxþ /) mice on B6-129 mixed background with pure C3H/HeJ mice were made generating
WwoxC3Hþ / N3/F1 (87.50% C3H genetic background). This C3H/HeJ mouse strain purchased from Jackson Laboratory does not carry the
mouse mammary tumor virus and females are known to develop spontaneous mammary tumors by age of 6–15 months (http://tumor.
informatics.jax.org/mtbwi/tumorFrequencyGrid.do;jsessionid¼D9E7769C40B059F342610671F2B3C2B8). To evaluate spontaneous mammary
tumors, 32 of N3-C3H female mice (8–18 months of matched age) were killed and autopsies were performed after CO2 asphyxiation. Tissues were
ﬁxed in 10% phosphate-buffered formalin and examined histologically by two pathologists after hematoxylin and eosin staining for the presence
of hyperplasia, DCIS and carcinomas. Tumor incidence was analyzed by two-tailed Fisher’s test and tumor multiplicity using one-way analysis of
variance. P-values o0.05 were considered statistically signiﬁcant. Italic indicates normal tissues.
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in WwoxC3Hþ /þ mice (Po0.001). The median age of
WwoxC3Hþ / mice that developed mammary tumors
was 13 months whereas the only wild-type animal
that developed tumors was 18 months old. These data
suggest that additional genetic alterations that accumu-
late with time might be required for tumor development.
Of note, only a small percentage of wild-type N3/F1-
C3H mice develop mammary tumors, perhaps, due to
the mixed genetic background of the colony. That such
statistical signiﬁcance was achieved with a relatively
small number of mice suggest that targeted deletion of
Wwox in the C3H background is indeed associated with
increased incidence of spontaneous mammary tumor
formation, though larger cohort of pure mice would be
necessary in the future to further validate these ﬁndings.
Mammary tumor phenotype in C3H-Wwoxþ / mice
Although mammary carcinomas were rare in
WwoxC3Hþ /þ mice (1/14), they were the most prevalent
tumor type inWwoxC3Hþ / mice, accounting for half of
the mice (Table 1). Mammary tumors originated in both
the inguinal and thoracic glands with a latency of 8–18
months. All of the female heterozygous mice that
developed mammary abnormalities developed ductal
carcinoma in situ (Figure 1A-b) and poorly differentiated
invasive ductal carcinomas (Figures 1A-c and d). Three
cases demonstrated squamous cell carcinomas, invasive
ductal carcinoma with epidermoid metaplastic features
(Figure 1A-e). Two animals (M26 and M27) developed at
least three separate primary mammary tumors in
different glands that were of different histological types
(Table 1). Epithelial hyperplasia was detected in female
WwoxC3H mice that did not develop mammary tumors
including wild-type mice. Cumulatively, these data
suggest that inactivation of Wwox in mice is associated
with mammary tumor phenotypes resembling those
developing in breast cancer (Guler et al., 2005; Nunez
et al., 2005; Aqeilan et al., 2007a).
M26N M21T M24TM26-DCIS M22T
CK14PRER
Normal
Tumor
Figure 1 Characterization of mammary tumors inWwox-heterozygous mice. (A) hematoxylin and eosin-stained sections of mammary
tissues fromWwoxC3Hþ / female mice ( 20); (a) normal murine mammary gland architecture is characterized by large adipocytes in
the stroma surrounding a sparse population of ducts. (b) Ductal hyperplasia and ductal carcinoma in situ (DCIS) commonly seen in
WwoxC3Hþ / female mice. (c–e) Invasive ductal carcinoma (c) with small acinar structures (d) and with epidermoid metaplastic
features (e). Magniﬁcation bars represents 100mm. (B) Expression of WWOX protein in mammary tissues from WwoxC3Hþ / female
mice ( 20) as described previously (Kurek et al., 2010). Polyclonal anti-WWOX antibody (Guler et al., 2009) at a dilution of 1:10 000
was used. Tumors were grouped into three categories (positive, reduced, negative) based on the intensity of cytoplasmic staining
in all tumor cells present on the slides. The ‘positive’ category was assigned when the intensity was equivalent to that found in
normal mammary glands from healthy tissues (f). The ‘reduced’ category was used for tumors with clearly diminished intensity (g, h)
and ‘negative’ category for IDC tumors with no WWOX immunostaining as in i and j. Magniﬁcation bars represents 100 mm.
(C) Expression of speciﬁc markers in mammary tissues fromWwoxC3Hþ / female mice ( 60) was performed as described (Gao et al.,
2005) in normal (upper) and tumors (lower). Magniﬁcation bars represent 20mm. Antibodies used were: mouse monoclonal anti-ER-a
antibody (ER: 6F11 1:25 from Novocastra Lab, Newcastle upon Tyne, UK), rabbit polyclonal anti-PR (PR: A0098 1:250 from
Dakocytomation, Carpinteria, CA, USA) and cytokeratine 14 (CK14: LL002, 1:8000 from AbD-Serotec, Raleigh, NC, USA).
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Frequent loss of WWOX, ER and PR in mammary
tumors from WwoxC3Hþ / mice
To analyze the status of the WWOX protein expression
in mammary tumors developed in WwoxC3Hþ / mice,
we next performed immunohistochemical analyses using
anti-WWOX antibody. WWOX expression was uni-
formly strong in the cytoplasm of the normal mammary
epithelial glands (Figure 1B-f). The intensity of WWOX
in ductal carcinoma in situ was attenuated as compared
with normal glands (Figure 1B-g). In 79% (11/14) of the
mammary tumors, there was partial or complete loss of
WWOX (Figures 1B-h–j). These results suggest that the
second wild-type allele of WWOX might be lost in
mammary tumors from WwoxC3Hþ / mice suggesting
loss of heterozygosity and that inactivation of both
WWOX alleles might accelerate mammary tumor
formation. Further, our data in mice are consistent
with reduced levels of WWOX in more advanced
stages (G-III) of human breast tumors (Aqeilan et al.,
2007a).
To better characterize these tumors, we next evaluated
the expression of ER and PR using immunohistochem-
ical staining. We found that in most of the poorly
differentiated tumors (grade III), expression of ER and
PR was lost (Table 1, Figure 1C). By contrast, ER
and PR staining was retained in the well-differentiated
(grade I) tumors, as in normal mammary glands
(Table 1). We have also examined the expression of
cytokeratine 14, a basal cell marker, in these tumors
and found that most tumors strongly expressed cytoker-
atine 14 (Figure 1C). In univariate analysis, WWOX loss
was more frequent in ER and PR negative basal-like
tumors (Table 2). These data suggest that characteristics
of mammary tumors in WwoxC3Hþ / mice resemble
those of human breast cancers where WWOX loss is
associated with triple negative basal-like (CK5/6) breast
cancers (Guler et al., 2009). This group, accounting for
15% of all breast cancers, is often characterized by
BRCA1 mutations. Being a DNA repair protein,
BRCA1 was previously shown to be important in
loss of fragile genes, such as WWOX (Turner et al.,
2002). Therefore, it is likely that inactivation of the
BRCA1 pathway in basal/triple negative-cancers
may contribute to loss of WWOX expression in
these cancers.
Depletion of WWOX in MCF7 cells is associated with
enhanced survival and anchorage-independent growth
The preceding observations suggest that WWOX loss
might enhance mammary tumor cell growth. Therefore,
we next investigated whether loss of WWOX expression
in ER-positive MCF7 cells enhances its tumorigenic
traits. To do so, we generated MCF7 cells containing a
stably integrated WWOX-targeting small hairpin RNA
expression vector. Immunoblot analysis conﬁrmed that
the expression of WWOX was reduced by more than
80% in two cell clones stably transfected with WWOX
small hairpin RNA (MCF7shWWOX), compared with
that of control small hairpin RNA-transfected cells
(Figures 2a and b). We next examined these cells for
their in vitro cell growth behavior. Colony formation
assay demonstrated that WWOX-depleted MCF7 cells
grew more colonies as compared with control cells
(Figure 2c). Next, we examined whether knockdown of
WWOX in MCF7 cells is associated with anchorage-
independent cell growth. We found that reduced
WWOX expression strongly enhanced growth in soft
agar of MCF7 cells (Figure 2d). These results suggest
that depletion of WWOX in MCF7 cells is associated
with a tumorigenic phenotype.
Knockdown of WWOX in MCF7 cells is associated with
reduced ER expression and function
Our results also suggest that WWOX loss might deprive
breast cancer cells of attributes, which when lost are
associated with high-grade malignancy, that is, loss of
ER expression (Figure 1C). To determine whether
knockdown of WWOX in MCF7 resembles loss of
WWOX in mammary tumors inWwoxC3Hþ / mice, we
examined if WWOX-depleted MCF7 cells display loss
of ER expression. We found that levels of ER were
signiﬁcantly downregulated in WWOX-depleted MCF7
cells compared with MCF7-EV cells as assessed by
western blot and real-time PCR analyses (Figures 2a
and e). To determine the functional relevance of this
downregulation, we examined the effect of Tamoxifen
(Tam) and 17b-estradiol (E2) treatments on the different
cell clones. Tam acts primarily through ER by modula-
tion of gene expression leading to inhibition of
proliferation of breast cancer cells (Radmacher and
Simon, 2000). To examine the sensitivity of WWOX-
depleted MCF7 cells to Tam treatment and E2, cells
were incubated in serum-free RPMI-1640 medium
containing 106 Tam or 109 E2 and cell proliferation
was determined. We found that although Tam treatment
attenuated control cell growth, WWOX-depleted MCF7
cells were signiﬁcantly less sensitive (Figure 2f). In the
presence of E2, WWOX-depleted MCF7 cells showed
reduced proliferation as compared with control MCF7
(Figure 2g). The modest differences in response to either
Tam or E2 could be attributed to the fact that WWOX
knockdown leads to downregulation and not to total
depletion of ER. Nevertheless, our ﬁndings suggest that
knockdown of WWOX levels in MCF7 ER-positive
cells is associated with tumorigenic traits and that
WWOX loss in breast cancer may affect ER signaling
Table 2 Association of WWOX immunoreactivity with expression
level of biomarkers in mammary tumors
ER PR CK14
WWOX 0.759a 0.737a 0.239
P value 0.001 0.003 0.324
N 16 14 19
Abbreviations: CK14, cytokeratine 14; ER, estrogen receptor; PR,
progesterone receptor.
Pairwise correlations of biomarkers were assessed using Spearman’s
correlation test.
aCorrelation is signiﬁcant at the 0.01 level (two-tailed). Correlations
were done on available cases excluding all n/a.
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contributing to mammary tumorigenesis. The molecular
mechanism underlying the tumor suppressor function of
WWOX in breast cancer cells remains to be fully
elucidated. Whether WWOX affects ER and PR
transactivation function is unknown. Recently, it was
reported that the WW domain-binding protein 2 is
essential for proper activation of PR and ER (Dhanan-
jayan et al., 2006). Intriguingly, WW domain-binding
protein 2 contains a PPxY motif that associates with
WW domain protein YAP (Sudol et al., 1995), leading
to ER and PR transactivation. As WWOX is known to
interact with PPxY-containing proteins as well (Salah
et al., 2010), it is possible that WWOX may associate
with WW domain-binding protein 2 and regulate ER/
PR signaling. Further analysis of WWOX-ER/PR
association in breast cancer would be required to better
explore WWOX molecular function.
mRNAs proﬁling using Affymetrix analysis
To further determine the molecular and cellular func-
tions of tumor suppressor WWOX in mammary tumor
development, we studied the differential expression of
mRNAs in invasive ductal carcinomas tumors developed
inWwoxC3Hþ / mice compared with control mammary
epithelial cells. The mRNAs were analyzed using mouse
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Figure 2 Phenotypes of WWOX depletion in MCF7 cells. (a) Establishment of MCF7 stable clones depleted of WWOX using
lentiviral vector carrying small hairpin RNA againstWWOX sequence. As control, empty vector (EV) was used. Cells were lysed using
0.5% NP40, 50mM Tris–HCL (pH7.5), 150mM NaCl, 0.5mM EDTA, 10% glycerol and 1 protease inhibitor (Calbiochem, Gibbstown,
NJ, USA). Western blot analysis of WWOX expression (using goat polyclonal anti-WWOX antibody, 1:1000, sc-20529) in MCF7-shWWOX
and -EV cells showing knockdown of 480% of WWOX expression in two clones is shown (CL1 and 3) (upper panel). Middle panel
shows expression of ER protein in WWOX-depleted MCF7 cells using anti-ER (H184) antibody (sc-7207). GAPDH served as loading
control. (b) WWOX mRNA relative expression in WWOX-depleted MCF7 cells as determined by real-time reverse transcriptase
(RT–PCR) analysis. Total RNA was isolated from the different clones followed by homogenizing in TRI-reagent (Sigma, St Louis,
MO, USA)) according to the manufacturer’s protocol. The cDNA was synthesized with oligo(dT) primers using the Super-Script ﬁrst
strand synthesis kit (Applied Biosystems (ABI), Foster City, CA, USA) according to the manufacturer’s protocol. Gene expression was
assessed by quantitative real time PCR (ABI) using primers listed in Supplementary Table 3. UBC cDNA served as internal control.
Columns, mean of triplicate samples from two independent experiments; bars, s.d. (c) Effect of WWOX depletion on survival, as
assessed by colony formation assay. MCF7 cells were plated at a density 5 102/well in a six-well plate in triplicate. After 10 days, cells
were ﬁxed with 70% ethanol, stained with Giemsa and colonies were counted. Columns, mean of triplicates samples; bars, s.e.m.,
(Po0.001). (d) Effect of WWOX depletion on anchorage-independent growth, as assessed by soft agar assay. Cells were plated between
two layers of agarose. The agar base was prepared by melting agar 1% in water at 42 1C and mixed with an equal volume of RPMI 2
containing 20% fetal calf serum. The plates were kept at 4 1C for at least 30min. The top layer was prepared by melting agarose 0.7%
in water that was mixed with an equal volume of RPMI 2 and 5000 cells/well in triplicate. This solution was then gently poured
on the base layer. The plates were incubated at 37 1C for 14–21 days. Colonies were detected by crystal violet staining and then
counted. Columns, mean of triplicates samples; bars, s.e.m. (Po0.001). (e) ESR1 mRNA relative expression in WWOX-depleted
MCF7 cells was determined by real-time RT–PCR analysis as in b. (f, g) Effect of Tamoxifen (f) and 17b-estradiol (g) treatment on
MCF7shWWOX growth rate. MCF7 cells were grown for 2 days without E2 and then incubated in serum-free medium containing
ethanol (0.2%), 106 Tam or 109 E2. Proliferating cells were analyzed at the indicated time points using an XTT (sodium
30-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) proliferation assay according to
the manufacturers instruction (Biological Industries, Beit Haemek, Israel). WWOX-depleted cells were less responsive to Tam and E2
treatment in the different clones. Relative living cells ratio represents the ratio between the optical density obtained from treated cells
to that obtained from untreated cells. ** represents Po0.01 and *** represents Po0.001 as analyzed by two tailed Student’s t-test.
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Affymetrix microarray gene-chip 430 2.0 arrays (Affymetrix,
Santa Clara, CA, USA). The analysis revealed numerous
genes that exhibited modiﬁed expression levels in the
mammary tumors (Supplementary Table 1). Principal
component analysis of all samples revealed that this
gene set effectively separates tumors from normal
epithelial cells (Supplementary Figure 1). To challenge
the statistical signiﬁcance of the microarray results,
we performed volcano analysis, using a threshold of
4-fold in gene expression with cutoff P-value o0.001
(Figure 3a). We identiﬁed 163 signiﬁcantly downregulated
and 129 signiﬁcantly upregulated genes in mammary
tumors (Supplementary Table 2). Examples of upregu-
lated transcripts in tumors include Sox4, Akt1, Scd2 and
Timp2 whereas Cxcl1, Il6 and Has1 were downregu-
lated. To validate some of the most signiﬁcant obser-
vations, we performed quantitative reverse transcriptase
PCR of various relevant transcripts. We conﬁrmed
the increase in expression of several genes in mouse
mammary tumors, including Scd2, Timp2 and Trim2
(Figure 3b). Similarly, a signiﬁcant decrease in
expression of several transcripts including Il-6, Timp4,
Has1 and Wwox was conﬁrmed in WwoxC3Hþ /
mammary tumors (Figure 3c). Although in some tumors
we observed a mixed pattern, likely due to contamina-
tion with stromal cells, these data suggest that WWOX
loss is associated with differential expression of tumor-
related genes.
Hierarchical unsupervised clustering of gene expres-
sion revealed the presence of 4 major clusters
(Figure 3d). Of these, two clusters included genes that
were strongly upregulated or downregulated in tumors
(tu) as compared with normal samples (no) (Figure 3d).
In order to better understand the biological function
of these genes, we used the Ingenuity (IPA) system
algorithms. We found multiple pathways that are altered
in tumors including cellular movement, cell-to-cell
signaling and interaction, cellular development, cellular
growth and proliferation and cell death (Supplementary
Table 3). Interestingly, several differentially expressed
genes identiﬁed in tumors of WwoxC3Hþ / mice are
well documented in human breast cancers and in other
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Figure 3 Affymetrix analysis of mammary tumors from Wwox-heterozygous mice. Total RNAs were isolated from ﬁve mammary
tumors from ﬁve WwoxC3Hþ / mice and three normal mammary epithelial glands from three control WwoxC3Hþ / littermate mice.
RNAs were hybridized with Affymetrix mouse gene-chip 430 2.0 arrays. (a) Volcano plot analysis of the differentially expressed genes
(log 2 scale) versus the P values of the genes (log 10 scale). The quality assurance, calibration, data normalization, principal
component analysis, and volcano plot for the Affymetrix cell format ﬁles were performed by Partek Genomics Suite 6.5 (Partek
Genomics, St Louis, MO, USA). Genes with a fourfold expression difference and cutoff P-valueso0.001 were deﬁned signiﬁcant. The
dots at the left upper side of the plot represent the statistically signiﬁcant downregulated genes in tumors, whereas those at the right
upper side represent the genes that were upregulated in tumors. (b, c) Real-time PCR validation of six deregulated genes in six
mammary tumors and two normal mammary epithelial cells. Total RNA was isolated using Tri-reagent (Sigma). RNA (1 mg) was
reversed transcribed using the iScript cDNA synthesis kit (Applied Biosystems). Real-time PCR was done using SYBR Green PCR
Master Mix (Applied Biosystems). Ubc was used as control. Columns, mean of triplicates samples; bars, s.d. Supplementary Table 4
shows list of primer sequence used for real-time PCR. (d) Heat map of commonly deregulated genes in Wwoxþ / mammary tumors
relative to normal mammary tissues. Negative fold change (transcripts with decreased expression in tumors) is represented in green and
positive fold change (transcripts with increased expression in tumors) is represented in red.
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mammary tumor mouse models (Hu et al., 2004; Klein
et al., 2007).
In conclusion, we propose that loss of WWOX
expression in mouse mammary tissues is associated with
signiﬁcant genetic and molecular changes that in turn
contribute to mammary tumor formation. These tumors
were mostly ER/PR-negative, a feature characterizing
aggressive tumors and those with worse outcome,
resembling loss of WWOX in human breast cancers.
Our ﬁndings may suggest thatWwoxC3Hþ /mice might
be used as a tool to study inactivation of WWOX in
human breast cancer.
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